Ocugen, Inc. (OCGN) SEC Filings & Earnings Calls

License agreement dependent on regulatory approvals and commercialization efforts by Roots; no guaranteed revenue.

“Roots has sole control over regulatory submissions; Ocugen will receive milestones only upon achievement.”

Clinical trial and regulatory risks inherent in gene therapy development; no new specific risks identified.

“Forward-looking statements caution about clinical trial results and regulatory approvals.”

Clinical trial failure risk for OCU410ST; negative interim data may impair pipeline value and regulatory prospects.

“DMC noted negative direction of treatment effect and considered futility; baseline imbalance confounds interpretation but does not eliminate risk.”

Clinical trial and regulatory risks; dependence on partnership for commercialization.

“FDA clearance for Phase 3 trial; RMAT designation; but still early stage.”

Going concern risk

“we have concluded that there is substantial doubt about our ability to continue as a going concern within one year after the date these condensed consolidated financial statements are issued.” · word for word

Clinical trial failure risk

“Topline Phase 3 data is expected in the first quarter of 2027, advancing OCU400 towards potential approval in the fourth quarter of 2027” · word for word

Financing risk

“If we are unable to obtain additional funding or otherwise successfully execute our plans when needed, we may be required to delay, reduce, or eliminate certain research and development programs” · word for word

Dilution Risk

“Adoption of the Authorized Shares Amendment would not affect the rights of the holders of currently outstanding common stock, except for effects incidental to increasing the number of shares of our common stock outstanding, such as dilution of the earnings per share and voting rights of current holders of common stock.” · word for word

Financing Dependency

“In order to implement our growth strategy, we may need to obtain financing through the issuance of equity securities.” · word for word

License is a binding term sheet; final agreement and regulatory approvals pending.

“Binding term sheet signed; no definitive agreement disclosed.”

Loss of CAO could create temporary gap in accounting leadership, but CFO is experienced.

“CAO resigned; CFO appointed as principal accounting officer.”

Increased leverage with $130M convertible notes; interest expense may impact cash flow.

“6.75% Convertible Senior Notes due 2034; $130M aggregate principal.” · word for word

Potential dilution of up to 8.1M shares upon conversion.

“Maximum of 8,108,108 shares issuable upon conversion of additional notes.”

Departure of Chief Medical Officer may impact clinical development timelines.

“CMO departure; interim appointment may cause temporary disruption.”

Going concern risk

“As of March 31, 2026, we had cash and cash equivalents of approximately $31.9 million. This amount will not meet our capital requirements over the next 12 months.” · word for word

Clinical trial failure risk

“We have not generated revenue from our product candidates to date, and have primarily funded our operations through the sale of common stock, warrants to purchase common stock, the issuance of convertible notes and debt, and grant proceeds.” · word for word

High debt burden and potential dilution from convertible notes.

“$115M convertible notes with 6.75% interest; conversion could dilute existing shareholders.”

Dilution risk: convertible notes may convert to common stock, diluting existing shareholders.

“risks related to the potential dilution to holders of the Company’s common stock; and uncertainties regarding the conversion price and other terms of the Notes.” · word for word

Debt service risk: 6.75% interest on $115M notes adds fixed cost.

“$115.0 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034” · word for word

Dilution risk from convertible notes conversion; potential stock price pressure.

“Convertible senior notes due 2034; shares issuable upon conversion.”

Debt servicing costs and refinancing risk; company may need additional capital.

“Company raising $115M to repay $32.7M loan and for general corporate purposes; indicates cash burn.”

Clinical trial failure risk

“Topline Phase 3 data is expected in the first quarter of 2027, advancing OCU400 towards potential approval in 2027.” · word for word

Financing risk / dilution

“In January 2026, the Company secured $22.5 million in gross proceeds through an underwritten registered direct offering of common stock led by RTW Investments” · word for word

Authorized share increase dependency

“the settlement of any vested awards would be deferred until our stockholders approve an increase to our authorized shares of common stock sufficient to satisfy the full issuance of such shares upon settlement” · word for word

Clinical and regulatory risks inherent in gene therapy development.

“Forward-looking statements caution about risks including clinical trial results and regulatory approvals.”

Clinical-stage biotech with no approved products; reliance on clinical trial outcomes.

“Forward-looking statements caution about risks; no revenue from product sales.”

Dilution from warrant exercise

“10,000,000 shares issued upon warrant exercise, increasing share count.”

Legal petition filed; nature and impact unknown from excerpt.

“Petition filed by Ocugen, Inc. in the Delaware Court of Chancery on February 12, 2026.” · word for word

Going concern risk

“Our recurring losses from operations raise substantial doubt about our ability to continue as a going concern for the next 12 months from the date of the consolidated financial statements included in this Annual Report are issued.” · word for word

Clinical trial failure risk

“Our product candidates are susceptible to the risks of failure inherent at any stage of product development, including the appearance of unexpected or unacceptable adverse events or failure to demonstrate efficacy in clinical trials.” · word for word

Regulatory approval delay risk

“The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming, and inherently unpredictable.” · word for word

Dilution risk

“Raising additional capital may cause dilution to stockholders, restrict our operations, or require us to relinquish rights to our technologies or product candidates.” · word for word

Novel technology risk

“Our product candidates generated from our modifier gene therapy platform are based on a novel technology and face an uncertain regulatory environment, which makes it difficult to predict the time and cost of product candidate development and subsequently obtaining regulatory approval.” · word for word

Clinical-stage biotech with no approved products; relies on financing and partnerships.

“Cash runway into Q4 2026; need for additional capital.”

Transition of principal financial officer may introduce operational risk.

“Ramesh Ramachandran will step down from the role of principal financial officer” · word for word

Dilution risk from equity offering

“Issuance of 15M shares at $1.50/share, representing significant dilution to existing shareholders”

Dilution risk from equity offering; potential cash burn or need for capital.

“15M shares at $1.50/share; net proceeds ~$20.8M for general corporate purposes, capex, working capital.”

Clinical trial data may not be indicative of final results; regulatory approval uncertain

“preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data” · word for word

Dilution risk from large PSU grant; potential overhang if milestones not met.

“9,369,604 PSUs granted; performance milestones may not be achieved.”

Going concern risk

“there is substantial doubt about our ability to continue as a going concern within one year after the date that the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q are issued.” · word for word

Cash burn risk

“As of September 30, 2025, we had cash of approximately $32.6 million. This amount will not be sufficient to fund our operations over the next 12 months.” · word for word

Dilution risk

“In August 2025, we closed a registered direct offering ... for the purchase and sale of 20,000,000 shares of common stock and warrants to purchase up to an aggregate of 20,000,000 shares of common stock.” · word for word

Debt covenant / conversion risk

“the Lender has the right to convert an aggregate amount of up to $6.0 million of the outstanding principal amount into shares of Common Stock at a conversion price per share equal to a 80% of the trading price on the date of conversion.” · word for word

Dependence on clinical trial success and regulatory approvals; no approved products or revenue.

“No revenue; clinical-stage biotech.”

Cash runway only into Q2 2026; additional financing needed.

“Extends cash runway into second quarter of 2026.”